Clinical data
| . | n (%) . | |
|---|---|---|
| No. patients | 110 (100) | |
| Age | ||
| Median (range), y | 61 (16-93) | |
| Sex | ||
| Female/male | 52/58 (47/53) | |
| Karnofsky performance status <90% | 7 (6.3) | |
| Properties of uveal melanoma | ||
| Largest tumor diameter (>14 mm)* | 62 (56) | |
| Ciliary body infiltration | 40 (36) | |
| Extraocular growth | 10 (9) | |
| Positive results of RT-PCR | ||
| Tyrosinase | 6 (55) | |
| MelanA/MART1† | 6 (5.5) | |
| PCR (tyrosinase or MelanA/MART1) | 11 (10) | |
| Follow-up interval from time of blood sampling | ||
| Median (range), mo | 22 (4-84) | |
| . | n (%) . | |
|---|---|---|
| No. patients | 110 (100) | |
| Age | ||
| Median (range), y | 61 (16-93) | |
| Sex | ||
| Female/male | 52/58 (47/53) | |
| Karnofsky performance status <90% | 7 (6.3) | |
| Properties of uveal melanoma | ||
| Largest tumor diameter (>14 mm)* | 62 (56) | |
| Ciliary body infiltration | 40 (36) | |
| Extraocular growth | 10 (9) | |
| Positive results of RT-PCR | ||
| Tyrosinase | 6 (55) | |
| MelanA/MART1† | 6 (5.5) | |
| PCR (tyrosinase or MelanA/MART1) | 11 (10) | |
| Follow-up interval from time of blood sampling | ||
| Median (range), mo | 22 (4-84) | |